Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis

Autoantibodies to Ro52 recently identified as TRIM21 are among the most common autoantibodies in systemic autoimmune rheumatic diseases, but their clinical association remains poorly understood. We undertook this study to determine the clinical and serologic associations of anti-Ro52/TRIM21 antibodi...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis research & therapy 2012-03, Vol.14 (2), p.R50-R50, Article R50
Main Authors: Hudson, Marie, Pope, Janet, Mahler, Michael, Tatibouet, Solène, Steele, Russell, Baron, Murray, Fritzler, Marvin J
Format: Article
Language:English
Subjects:
Adult
Aged
Analysis
Autoantibodies
Autoantibodies - biosynthesis
Autoantibodies - blood
Biomarkers - blood
Cohort Studies
Cross-Sectional Studies
Female
Humans
Male
Middle Aged
Ribonucleoproteins - immunology
Scleroderma (Disease)
Scleroderma, Systemic - diagnosis
Scleroderma, Systemic - immunology
Scleroderma, Systemic - metabolism
Systemic scleroderma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Autoantibodies to Ro52 recently identified as TRIM21 are among the most common autoantibodies in systemic autoimmune rheumatic diseases, but their clinical association remains poorly understood. We undertook this study to determine the clinical and serologic associations of anti-Ro52/TRIM21 antibodies in patients with systemic sclerosis (SSc). Detailed clinical data and sera from 963 patients with SSc enrolled in a multicenter cohort study were collected and entered into a central database. Antibodies to Ro52/TRIM21 and other autoantibodies were detected with an addressable laser-bead immunoassay and different enzyme-linked immunosorbent assay (ELISA) systems. Associations between anti-Ro52/TRIM21 antibodies and clinical and other serologic manifestations of SSc were investigated. Anti-Ro52/TRIM21 antibodies were present in 20% of SSc patients and overlapped with other main SSc-related antibodies, including anti-centromere (by immunofluorescence and centromere protein (CENP)-A and CENP-B ELISA), anti-topoisomerase I, anti-RNA polymerase III, and anti-Pm/Scl antibodies. Anti-Ro52/TRIM21 antibodies were strongly associated with interstitial lung disease (odds ratio (OR), 1.53; 95% confidence interval (CI), 1.11 to 2.12; P = 0.0091) and overlap syndrome (OR, 2.06; 95% CI, 1.01 to 4.19; P = 0.0059). Anti-Ro52/TRIM21 antibodies were the second most common autoantibodies in this SSc cohort. In SSc, anti-Ro52/TRIM21 antibodies may be a marker of interstitial lung disease and overlap syndrome.
ISSN:1478-6354
1478-6362
1478-6354
DOI:10.1186/ar3763